Tyligand Bioscience

Shanghai, China · Founded 2018 · In IPO Registration

Developer and manufacturer of oral oncology drugs and antibody-drug conjugate platforms designed for KRAS-mutated and other solid tumors. Tyligand Bioscience is based in Shanghai, China and was founded in 2018. Its last reported valuation was $222 million in Jan 2026. It has raised $111 million.

Last reported valuation
$222.2M
Oct 2026
Priced at
—
Total raised
$110.6M
Last round
—

Who backs Tyligand Bioscience?

14 investors
InvestorType
Suzhou Oriza Holdings CorporationAsset manager
K2VCOther
Tailong VCOther
Suzhou Yuanfeng Capital ManagementOther
VI VenturesVenture capital
BOHE Angel Fund—
Calor Capital—
China Medical System—
LAV (Lilly Asia Fund)—
Med-Fine Capital—
+ 4 more investors · a free account shows the complete list
The directory is free. Investor activity — the working column — is Pro.Unlock prospecting columns

Membership and data by Private Market View

Tyligand Bioscience investors

14 investors are on record for Tyligand Bioscience, including Suzhou Oriza Holdings Corporation, K2VC, Tailong VC and Suzhou Yuanfeng Capital Management.

Free account
More of Tyligand Bioscience with a free account
  • ·The complete investor list: 14 names
  • ·Watch Tyligand Bioscience: the Monday email on marks, rounds and moves
Create free account
No card required

Membership and data by Private Market View

For fundraisers
Work this list, don’t just read it

These 14 firms already write checks for companies like Tyligand Bioscience. Build the wider list: every firm that has backed a company like this one, ranked by how often and how recently.

Find investors like these →

Membership and data by Private Market View